This is an IDEAL opportunity to have YOUR say and be heard by our politicians.
The Australian health and medical research sector is at a crisis point due to over a decade of inadequate investment in the National Health and Medical Research Council (NHMRC). Please join our campaign to put health and medical research funding firmly on the political agenda by completing your details below to auto-generate an email to your Federal Electoral candidates.
It will take you less than one minute but will put our political leaders on notice that more investment in health and medical research is urgently needed to secure a healthy future for all Australians.
People with systemic scleroderma (SSc) who have certain autoantibodies are at increased risk of developing pulmonary hypertension, or high pressure in the blood vessels of the lungs, according to a study in the U.S.
Ever wondered why your eyes feel so dry? Dr. Elizabeth Price (UK) goes over the mechanics of how eyes are lubricated, and what you can do to help them stay hydrated.
Can you imagine how it would impact life with SSc if we had a way to accurately predict whether or not Raynaud's was a warning sign for the condition?
New research suggests that using the VEDOSS criteria could do just that - allowing for earlier diagnosis and potentially even the use of stratified medicine down the line.
Local injection with botulinum toxin A (BTX-A) safely and effectively reduces Raynaud’s phenomenon (RP) and nailfold small blood vessel, or capillary, abnormalities in women with scleroderma, according to data from a small study in China. Treatment also led to significant improvements in upper limb function in women with limited scleroderma, but not in those with diffuse disease...
SRUK's latest video takes a look at how you can combat dry mouth, from preventative measures to practical tips:
Dry mouth - or xerostomia - can be caused by scleroderma or many other conditions. It can be unpleasant and make life uncomfortable, and can contribute to tooth decay.
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Gesynta Pharma’s GS-248, its oral therapy for people with systemic sclerosis (scleroderma). Orphan drug status aims to encourage therapies for rare diseases through benefits such as seven years of market exclusivity and exemption from FDA fees. “The orphan drug designation granted to our drug candidate GS-248
Dr. Price talks through some really useful information in the pre-recorded webinar above, including how to deal with dry eyes and antibodies that can indicate a vulnerability to scleroderma.
Fat-derived cells from adults with diffuse cutaneous scleroderma that are then injected under the skin of the hands led to clinically meaningful improvements in hand function, according to published data from the Phase 3 STAR I clinical trial.
The main findings of scleroderma are thickening and tightening of the skin and inflammation and scarring of many body parts, leading to problems in the lungs, kidneys, heart, intestinal system, and other areas.
Scleroderma Queensland Support Group